Background： The clotting system abnormalities are the common complication in cancer patients. The aim of this retrospective study was to evaluate the coagulation state, clinical features, and treatment in cancer pati...Background： The clotting system abnormalities are the common complication in cancer patients. The aim of this retrospective study was to evaluate the coagulation state, clinical features, and treatment in cancer patients by routine tests. Methods： A total of 2328 patients with different types of cancer were classified as the positive group （n = 1419, including 53 patients with thrombosis） and the negative group （n = 909） based on D-dimer （DD） value. Of the 2328 cases, 354 were admitted for chemotherapy. Hemostasis test and complete blood count （CBC） were perfbrmed during treatment or following-up. Results： This study showed that the hypercoagulable state was affected not only by clinical staging （P 〈 0,0001） but also by metastasis site （P 〈 0.0001 for bone vs. lung）. Compared to negative DD group, the higher fibrinogen level, the extended activated partial thromboplastin time, and prothrombin time interacted markedly with disease clinical stage （P 〈 0.05） in the positive group. Between positive DD groups with and without thrombus, the significantly statistic difference in white blood cell （WBC） and DD （P 〈 0.05） rather than in red blood cell （RBC） and platelet count was observed. However, the higher DD level was not correlated with WBC, RBC, and platelet count in the positive DD group. Furthermore, the hypercoagulable plasma profile in cancer patients was moderated 2-3 weeks alter chemotherapy （P 〈 0.05 for first six cycles）. Conclusions： The routine hemostatic parameters and CBC are valuable to assessment for thrombosis and chemotherapy even for disease prognosis.展开更多
文摘Background： The clotting system abnormalities are the common complication in cancer patients. The aim of this retrospective study was to evaluate the coagulation state, clinical features, and treatment in cancer patients by routine tests. Methods： A total of 2328 patients with different types of cancer were classified as the positive group （n = 1419, including 53 patients with thrombosis） and the negative group （n = 909） based on D-dimer （DD） value. Of the 2328 cases, 354 were admitted for chemotherapy. Hemostasis test and complete blood count （CBC） were perfbrmed during treatment or following-up. Results： This study showed that the hypercoagulable state was affected not only by clinical staging （P 〈 0,0001） but also by metastasis site （P 〈 0.0001 for bone vs. lung）. Compared to negative DD group, the higher fibrinogen level, the extended activated partial thromboplastin time, and prothrombin time interacted markedly with disease clinical stage （P 〈 0.05） in the positive group. Between positive DD groups with and without thrombus, the significantly statistic difference in white blood cell （WBC） and DD （P 〈 0.05） rather than in red blood cell （RBC） and platelet count was observed. However, the higher DD level was not correlated with WBC, RBC, and platelet count in the positive DD group. Furthermore, the hypercoagulable plasma profile in cancer patients was moderated 2-3 weeks alter chemotherapy （P 〈 0.05 for first six cycles）. Conclusions： The routine hemostatic parameters and CBC are valuable to assessment for thrombosis and chemotherapy even for disease prognosis.
